Clinical Trials
25 trialsPEMIGIST
Dana-Farber Cancer Institute
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PERELI
Lund University Hospital
AcSé PEMI
UNICANCER
PEGASUS
European Association of Urology Research Foundation
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
FINPROVE
Helsinki University Central Hospital
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
DRUP
The Netherlands Cancer Institute
ROME
Fondazione per la Medicina Personalizzata
Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors
Tianjin Medical University Second Hospital
A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant
Sun Yat-sen University
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy
Zhejiang Cancer Hospital
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
Tianjin Medical University Cancer Institute and Hospital
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology